PerkinElmer Introduces New Multispecies In Vivo Imaging Solution for Drug Development at American Association for Cancer

ORLANDO, Fla.--(BUSINESS WIRE)-- PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, today announced a new Multispecies Imaging Module (MSIM) for PerkinElmer’s Fluorescence Molecular Tomography In Vivo Imaging Systems (FMT® 1500 or FMT® 2500LX). The new module enables researchers to generate 3D datasets of animal models relevant to disease research, including imaging capability for larger animals.

The multispecies imaging module allows researchers for the first time to deploy non-invasive fluorescence molecular tomography (FMT) to generate quantitative 3D datasets from both small and large animal models. Imaging larger animals has taken on greater importance since many disease models have been specifically developed based on rats, hamsters and guinea pigs, in addition to small animals such as mice. These disease states include oncology models and transplantation pathologies, autoimmune disorders, rheumatoid arthritis models, cardiovascular diseases, as well as metabolic diseases.

The 3D quantitative image datasets generated by the MSIM can be used for biodistribution, disease progression and therapeutic response studies early in drug development pipelines. This enables researchers to filter out drug candidates that might otherwise have failed very expensively later in the drug development process.

“PerkinElmer is delighted to offer preclinical researchers expanded imaging and dataset-building capabilities for understanding disease,” said Achim von Leoprechting, vice president and general manager, Imaging and Detection Technologies, Bio-discovery, PerkinElmer, Inc. “Our new imaging module provides researchers working with large animal models with greater data quality and visibility. This technology gives them the same data building capability that they currently have with the conventional baseline of mice imaging – for animals up to 20 times larger than mice – for more disease-relevant data.”

The new MSIM docking station holds either the larger species cassette or an adapter that holds the original mouse cassette, allowing for sequential scans of rats, hamsters, guinea pigs and mice interchangeably. The proprietary fluorescence agent portfolio works equally well in the different animal models.

In addition, PerkinElmer’s TrueQuant™ analysis software has been upgraded for the new MSIM enabling fast reconstruction for the large image data files collected during a larger species scan.

To learn more visit PerkinElmer at booth #121 or

About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $1.7 billion in 2010, has about 6,200 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at


Edelman (On behalf of PerkinElmer, Inc.)
Amanda L. Connolly, 404-832-6785
[email protected]

KEYWORDS:   United States  North America  Florida

INDUSTRY KEYWORDS:   Stem Cells  Health  Biotechnology  Cardiology  Clinical Trials  Genetics  Medical Devices  Pharmaceutical  Other Health  Research  FDA  Science